Release date: 2017-09-22
On August 23, 2017, the US Food and Drug Administration (FDA) approved another IND report for Unum Therapeutics' ACTr therapy, which is combined with the humanized antibody SEA-BCMA for ACTR087-T cell therapy. Recurrent or refractory multiple myeloma.
Unum expects to begin drug treatment in the first quarter of 2018. In order to provide a suitable dosage regimen for future clinical studies, and to assess the patient's response to treatment, as well as the safety and tolerability of SEA-BCMA.
Currently, another of the company's experiments on ACTR087 is currently undergoing a phase I trial (NCT02776813) in combination with rituximab for the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphocytes in adult patients. tumor.
What is ACTR therapy?
ACTR, an antibody-coupled T cell receptor, is a chimeric protein that utilizes receptor binding components in human NK cells and T cells, creating a new way to kill cancer cells. The ACTR chimeric protein with T cells can bind to an antibody and then specifically bind to antigens on the surface of cancer cells, using T cells to attack cancer.
ACTR (Note: the picture comes from the network)
Advantages of ACTR therapy
ACTR technology is not limited to a single specific tumor cell antigen compared to other T cell therapies such as CAR-T and TCR-T cell therapy. Therefore, it is possible to apply treatment of many different types of cancer and promote its use in the treatment of various cancers.
Unum's strategy involves using the patient's own T cells and modifying them to express an ACRT protein. When ACRT binds to antibodies that bind to cancer cells, ACRT-T cells will specifically target antibody-labeled cancer cells.
In recent years, cancer research has made great progress, but there are still a large number of unmet medical needs in the treatment of diseases, because almost all patients are ultimately difficult to treat. The author believes that ACTR technology as a new cancer treatment method, there are two cancer treatment programs have entered the clinical phase I stage, it is still gratifying, but the safety, tolerability and anti-cancer activity of this treatment method All need to be verified by a large number of clinical trials. The long road is long, and it takes many years for ACTR technology to take advantage of multi-target cancer treatment.
Article source: https://
Source: CPhI Pharmaceutical Online (micro-signal cphi_cn)
Young Green Plants Honey Drink
Young Green Plants Honey Drink,Plants Honey Drink,Honey Fruit Tea,Honey Herbal Tea
Hengshui Shanzhi Health Drink Co., Ltd , https://www.grasspowder-sz.com